Overview of Dr. Voss
Dr. Martin Voss is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Albert Ludwigs University Faculty of Medicine and has been in practice 12 years. He is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
MSK Sidney Kimmel Center for Prostate and Urologic Cancers
353 East 68th Street
New York, NY 10021- Is this information wrong?
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
Albert Ludwigs University Faculty of MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2009 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Start of enrollment: 2013 Apr 01
- A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Start of enrollment: 2015 Oct 01
- Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma.Matulewicz, R. S., Stephen W Reese, Lennert Eismann, Charlie White, Juan Arroyave Villada, Sari Khaleel, Irina Ostrovnaya, Katiana Vazquez-Rivera, Maria I Carlo, Darre...> ;Urologic Oncology. 2024 Feb 1
- A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.Ritesh R Kotecha, Sahil D Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Rachel Jacobi, Mark Zucker, Ed Reznik, Deaglan McHugh, Neil J Shah, Emily Feld, David H A...> ;European Urology Oncology. 2023 Nov 7
- LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.Toni K Choueiri, Thomas Powles, Martin H Voss, Elizabeth R Plimack, Howard Gurney, Yue Song, Rodolfo F Perini, Karla Rodriguez-Lopez, Brian I Rini> ;Future Oncology. 2023 Dec 1
- Join now to see all
Journal Articles
- Checkpoint Inhibitors and Other Novel Immunotherapies for Advanced Renal Cell CarcinomaMartin H Voss, Robert J Motzer, Nature
Lectures
- Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogen...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell ca...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- Genomic Classifiers in Renal Cell CarcinomaFebruary 2018
Press Mentions
The Latest Breakthroughs That Could Improve Kidney Cancer TreatmentNovember 1st, 2022
ASCO GU 2020: Dr. Albiges Recounts Exciting Research in RCCMarch 25th, 2020
Kidney Cancer: Vaccine-Based ApproachesNovember 8th, 2017- Join now to see all
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York- Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
